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The overall performance of percutaneous coronary inter-
vention (PCI) in the United States has been slightly
decreasing over the past 5 years (1). Meanwhile, patients
older than 75 years of age account for an increasing
proportion of cases of PCI among the general population,
and annual rates of PCI have quadrupled in this subset of
patients (2). Multicenter registries of all-comer PCIs in the
United States and Europe have reported similar proportions
of w12% of patients 80 years of age (2–4).See page 1371Octogenarians undergoing PCI are typically burdened by
multiple comorbidities and a doubled risk of mortality (4,5).
In comparison with younger patients, they are more likely
to have diabetes mellitus, chronic renal insufﬁciency, left
ventricular dysfunction, multivessel disease (MVD), previous
myocardial infarction (MI) or coronary artery bypass graft-
ing, and increased tortuosity and calciﬁcation of their aorta
and coronary and peripheral arteries; all are reasons for
advanced procedural complexity (3,6). Interventions on
calciﬁed plaques are associated with increased frequency of
periprocedural complications and inadequate stent expansion
resulting in higher rates of in-stent restenosis (7), whereas
tortuous vessels increase vascular access site complications
and the difﬁculty of coronary device deployment (8).
Increased bleeding events in elderly patients are due to age-
related reduced weight and muscle mass, altered drug
metabolism, and changes in hemostasis (9). Moreover, the
indication for surgical revascularization has become better
deﬁned in patients with MVD (10,11), which is related to
the 16.5% decrease in the prevalence of MVD among
younger and operable patients undergoing PCI. Conversely,
the prevalence of MVD in elderly patients undergoing PCI
remains constant (2).*Editorials published in the Journal of the American College of Cardiology reﬂect the
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higher-risk patient subset and increasing complexity) in the
PCI population, de Belder et al. (12) should be congratu-
lated on conducting a dedicated clinical study of elderly
patients. The results of the XIMA (Xience or Vision stents
for the Management of Angina in the Elderly) trial, pub-
lished in this issue of the Journal, showed that patients
80 years of age undergoing PCI with drug-eluting stents
(DES) had similar rates of all-cause death, stroke, and major
hemorrhage, but reduced incidence of MI and target vessel
revascularization when compared with bare-metal stent
(BMS) implantation (12). The XIMA trial adds valuable
knowledge to clinical decision making for several reasons.
Most importantly, elderly patients are often excluded or
under-represented in randomized trials. Because no other
randomized trials have speciﬁcally addressed stent strategies
in elderly patients, the results of DES in those patients have
been based on large retrospective registry analyses thus far
(13,14). Of particular interest is 1 previous randomized trial
in elderly patients showing that PCI by radial access has
higher technical success and lower complication rates in
terms of bleeding than the femoral approach (15). This was
conﬁrmed in the pre-speciﬁed subgroup analysis of the
XIMA trial.
However, the ﬁndings of the XIMA trial have to be
considered in the light of several methodological limitations.
The study was powered for the primary endpoint of 1-year
composite of death, MI, stroke, revascularization, or major
hemorrhage, with an estimated event rate of 12% for the DES
arm and 20% for the BMS arm. Noncardiac death was more
than doubled in the DES group (5.3% vs. 2.5%; p ¼ 0.04),
thereby causing an imbalance within the groups because we
would not expect noncardiac mortality to be affected by the
choice ofDES versus BMS. It is unclear whether bleedingwas
regarded as a reason for noncardiac death. The endpoint of
major hemorrhage was deﬁned by major Thrombolysis In
Myocardial Infarction bleeding (1.7% in the BMS group and
2.3% in the DES group; p ¼ 0.62). The occurrence of major
hemorrhage was greater in the DES group from 6 to 12
months (1.0% vs. 0.2%; p¼ 0.22), but did not reach statistical
signiﬁcance because the trial was underpowered to answer the
isolated question of harm by bleeding. It would be interesting
to review the long-term follow-up in regard to bleeding issues.
Reporting bleeding endpoints also by Bleeding Academic
Research Consortium or including Thrombolysis In
Myocardial Infarction minor bleeding might have changed
the outcome measure with respect to 1-year mortality.
Bleeding events also relate to dual antiplatelet therapy
(DAPT) therapy and its duration. At 1 year, the rates of
DAPT were 32% and 94% in the BMS and DES groups,
respectively. In most of these patients, discontinuation of
DAPT was due to treatment disruption by noncompliance
or treatment withdrawal for clinical concerns. Recently,
disruption of DAPT in DES-treated patients was found to
have a 12-fold hazard for major adverse cardiac events within
the ﬁrst 7 days after disruption (16). Other reports have
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1377questioned the utility of the continuation of DAPT beyond
6 months with respect to risk reduction of stent thrombosis
(17); this may be particularly applicable to everolimus-eluting
DES because they are associated with a low incidence of stent
thrombosis and restenosis (18). The XIMA trial would have
provided very valuable lessons on duration, interruption, and
disruption of DAPT if detailed data on these variables were
available. Bleeding (and perhaps noncardiac death) rates
might have been lower if the duration of DAPT were shorter.
Furthermore, the primary endpoint treatment beneﬁt was
driven by MI and target vessel revascularization. It is unclear
whether the higher MI rate in the BMS group (3.5% at
1 month, 8.7% at 1 year) was associated with periprocedural
MI, stent thrombosis, restenosis, plaque rupture in non-
target vessels, or severe demand ischemia due to noncardiac
comorbidities.
Finally, 800 patients were recruited from 20 centers over
36 months, equaling an average of 1.1 patients per center per
month. This certainly indicates a highly-selected population,
limiting the generalizability of the results.
In conclusion, a clinical strategy of everolimus-eluting
stenting via radial access in elderly patients appears to be
attractive because it reduces vascular complications while
improving rates of MI and target vessel revascularization. In
addition, the duration of DAPT in potentially frail patients
remains an important question, and outcomes may improve if
the duration of DAPT can be shortened safely. A crucial
aspect of this trial and any other clinical investigation in elderly
patients is AN understanding of the noncardiac mortality
trends and their relationship with treatment arms and primary
outcome measures. The only way to decipher these questions
is to conduct more trials including elderly patients.
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